Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Zavante Therapeutics Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections

January 19, 2017
SAN DIEGO, Jan. 19, 2017 /PRNewswire/ -- Zavante Therapeutics, Inc., a privately-held, late clinical-stage biopharmaceutical company, today announced the completion of patient recruitment and treatment in the ZEUS multinational pivotal…

Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study

January 18, 2017
BOSTON, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that…

Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia

December 22, 2016
NEW HAVEN, Conn., Dec. 22, 2016 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today that it has enrolled the first patient in its potentially pivotal Phase…